Imipenem/Cilastatin Aptapharma

Imipenem, the active ingredient in Imipenem/Cilastatin Aptapharma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. Combined with cilastatin, it treats a range of serious bacterial infections in hospitalized patients, including complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, nosocomial pneumonia and septicemia.

GNH USA supplies Imipenem/Cilastatin Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Imipenem/Cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative and Gram‑positive organisms. - Skin and soft‑tissue infections: treats severe infections caused by susceptible bacteria. - Nosocomial pneumonia: effective against hospital‑acquired respiratory pathogens. - Septicemia: rapidly clears bloodstream infections caused by susceptible organisms.

Adverse reactions may occur with any antimicrobial therapy. Monitoring for side effects is recommended.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: mild transaminase increase. - Injection site pain: discomfort at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Severe renal impairment: worsening kidney function. - Thrombocytopenia: low platelet count. - Stevens‑Johnson syndrome: rare severe skin reaction.

Careful assessment and monitoring are essential when using this injectable antibiotic. - Renal function assessment: adjust dosage in patients with impaired kidney function. - Seizure risk: avoid in individuals with a history of seizures or CNS disorders. - Hypersensitivity: do not use in patients with known allergy to beta‑lactams. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Concomitant nephrotoxic drugs: monitor renal function closely when combined with other nephrotoxic agents. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Drug interactions can affect efficacy and safety; review patient medication lists.

Major Interactions (Avoid): - Valproic acid: reduces valproate levels, risking seizure breakthrough. - Other carbapenems: concurrent use may increase toxicity without added benefit. - Renal toxic agents (e.g., aminoglycosides): may exacerbate kidney injury.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance, requiring dose adjustment. - Anticoagulants (warfarin): monitor INR for potential changes. - Oral contraceptives: possible reduction in effectiveness, advise alternative contraception.